J E Meca-Lallana, S Martínez Yélamos, S Eichau, M Ángel Llaneza, J Martín Martínez, J Peña Martínez, V Meca Lallana, A M Alonso Torres, E Moral Torres, J Río, C Calles, A Ares Luque, L Ramió-Torrentà, M E Marzo Sola, J M Prieto, M L Martínez Ginés, R Arroyo, M Á Otano Martínez, L Brieva Ruiz, M Gómez Gutiérrez, A Rodríguez-Antigüedad Zarranz, V G Sánchez-Seco, L Costa-Frossard, M Á Hernández Pérez, L Landete Pascual, M González Platas, C Oreja-Guevara
The last consensus statement of the Spanish Society of Neurology's Demyelinating Diseases Study Group on the treatment of multiple sclerosis (MS) was issued in 2016. Although many of the positions taken remain valid, there have been significant changes in the management and treatment of MS, both due to the approval of new drugs with different action mechanisms and due to the evolution of previously fixed concepts. This has enabled new approaches to specific situations such as pregnancy and vaccination, and the inclusion of new variables in clinical decision-making, such as the early use of high-efficacy disease-modifying therapies (DMT), consideration of the patient's perspective, and the use of such novel technologies as remote monitoring...
January 16, 2024: Neurología